CD8A and neoplasm: Patients who showed a good response to pembrolizumab demonstrated abundant preexisting tumor-infiltrating lymphocytes , a diverse pretreatment TCR repertoire, and a high proportion of stem-like exhausted cells in dysfunctional CD8+ TILs.